Randomised Controlled Trial Evaluating Strategies to Optimize Disease Activity Control in RA Patients Treated With Infliximab in Clinical Practice.

Trial Profile

Randomised Controlled Trial Evaluating Strategies to Optimize Disease Activity Control in RA Patients Treated With Infliximab in Clinical Practice.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms RE-CUBE
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Jul 2012 Additional trial locations added as reported by European Clinical Trials Database record.
    • 26 Jan 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top